Real-world comparative effectiveness of FOLFOX, FOLFIRI, and CapOx as second-line chemotherapy for advanced biliary tract cancer
Abstract
Background: Advanced biliary tract cancer (BTC) has a poor prognosis following progression on first-line gemcitabine plus cisplatin. However, evidence comparing second-line chemotherapy regimens remains limited. This study aimed to compare the effectiveness and safety of fluorouracil, leucovorin, and oxaliplatin (FOLFOX); fluorouracil, leucovorin, and irinotecan (FOLFIRI); and capecitabine plus oxaliplatin (CapOx).
Patients and Methods: Adults with advanced BTC who received first-line gemcitabine plus cisplatin followed by second-line FOLFOX, FOLFIRI, or CapOx between January 2010 and July 2025 were identified from the TriNetX Global Collaborative Network. Patients who subsequently received molecularly targeted therapies were excluded. The study included 825 patients receiving FOLFOX, 184 receiving FOLFIRI, and 149 receiving CapOx; after 1:1 propensity score matching, the respective comparisons included 182 and 149 patients per group. Overall survival (OS) and treatment-related adverse events were compared between the matched cohorts.
Results: The median OS was comparable between FOLFOX and FOLFIRI (5.7 months vs 5.8 months, P = .958) and between FOLFOX and CapOx (5.7 months vs 5.8 months, P = .803). The overall adverse event profiles were also comparable. However, FOLFOX was associated with lower rates of neutropenia but higher rates of thrombocytopenia than FOLFIRI. In contrast, FOLFOX and CapOx demonstrated similar toxicity despite modest differences in anemia and thrombocytopenia.
Conclusion: This real-world study demonstrates comparable survival outcomes among FOLFOX, FOLFIRI, and CapOx as second-line chemotherapies for advanced BTC. These findings support individualized regimen selection based on patient characteristics and toxicity profiles.
Related
- Cost-effectiveness of disitamab vedotin plus toripalimab versus chemotherapy alone as first-line treatment for HER2-overexpressing advanced urothelial carcinoma: a cost-effectiveness analysis from the Chinese healthcare system perspective
- Comparative effectiveness of first-/second-generation EGFR-TKI combination therapy versus third-generation EGFR-TKI monotherapy in untreated locally advanced or metastatic EGFR-mutant NSCLC: a real-world, retrospective study in China
- Cost-effectiveness analysis of ivonescimab plus chemotherapy in advanced squamous NSCLC: a Chinese healthcare system perspective with U.S. pricing scenario exploration
- Cost-effectiveness of datopotamab deruxtecan versus chemotherapy as a first-line treatment for patients with advanced triple-negative breast cancer
- Comparative efficacy and toxicity of two versus three induction chemotherapy cycles in locally advanced nasopharyngeal carcinoma: a propensity score matching analysis.
BibTeX
@article{chao2026realworld,
title = {{Real-world comparative effectiveness of FOLFOX, FOLFIRI, and CapOx as second-line chemotherapy for advanced biliary tract cancer}},
author = {Chun-Yang Chao and Kuan-Yu Tseng and Hsin-Chen Lin and Yu-Hsuan Shih},
journal = {The Oncologist},
year = {2026},
month = oct,
doi = {10.1093/oncolo/oyag424},
url = {https://doi.org/10.1093/oncolo/oyag424},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-world comparative effectiveness of FOLFOX, FOLFIRI, and CapOx as second-line chemotherapy for advanced biliary tract cancer
AU - Chun-Yang Chao
AU - Kuan-Yu Tseng
AU - Hsin-Chen Lin
AU - Yu-Hsuan Shih
PY - 2026
DA - 2026/10/21
JO - The Oncologist
DO - 10.1093/oncolo/oyag424
UR - https://doi.org/10.1093/oncolo/oyag424
AB - Background: Advanced biliary tract cancer (BTC) has a poor prognosis following progression on first-line gemcitabine plus cisplatin. However, evidence comparing second-line chemotherapy regimens remains limited. This study aimed to compare the effectiveness and safety of fluorouracil, leucovorin, and oxaliplatin (FOLFOX); fluorouracil, leucovorin, and irinotecan (FOLFIRI); and capecitabine plus oxaliplatin (CapOx). Patients and Methods: Adults with advanced BTC who received first-line gemcitabine plus cisplatin followed by second-line FOLFOX, FOLFIRI, or CapOx between January 2010 and July 2025 were identified from the TriNetX Global Collaborative Network. Patients who subsequently received molecularly targeted therapies were excluded. The study included 825 patients receiving FOLFOX, 184 receiving FOLFIRI, and 149 receiving CapOx; after 1:1 propensity score matching, the respective comparisons included 182 and 149 patients per group. Overall survival (OS) and treatment-related adverse events were compared between the matched cohorts. Results: The median OS was comparable between FOLFOX and FOLFIRI (5.7 months vs 5.8 months, P = .958) and between FOLFOX and CapOx (5.7 months vs 5.8 months, P = .803). The overall adverse event profiles were also comparable. However, FOLFOX was associated with lower rates of neutropenia but higher rates of thrombocytopenia than FOLFIRI. In contrast, FOLFOX and CapOx demonstrated similar toxicity despite modest differences in anemia and thrombocytopenia. Conclusion: This real-world study demonstrates comparable survival outcomes among FOLFOX, FOLFIRI, and CapOx as second-line chemotherapies for advanced BTC. These findings support individualized regimen selection based on patient characteristics and toxicity profiles.
SN - 1083-7159
SN - 1549-490X
ER -